Compare Repligen Corporation Common Stock (RGEN) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Tidewater Inc — how do they compare? Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B), while Tidewater Inc trades at $83.01 (market cap $4.12B). The key difference: Repligen Corporation Common Stock is far larger — about 2.7× Tidewater Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Tidewater Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Tidewater Inc for 27 Days on average.
| RGEN | TDW | |
|---|---|---|
Market Cap | $11.31B | $4.12B |
Volume | 1,216,919 | 718,273 |
Sector | Health | Energy |
52-Week High | $194.57 | $100.61 |
52-Week Low | $102.87 | $47.29 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $11.20B | $4.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Tidewater (TDW) trades at $86.97, up 0.6% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with an 18.34% net income margin and 19.49% ROE, though recent quarterly EPS missed expectations. The acquisition of Wilson Sons Ultratug (Business Wire, 2026-08-31) expands its offshore services footprint. Analyst consensus price target is $105.50, implying potential upside from current levels.
The outlook is cautiously optimistic, supported by solid cash flow and institutional interest, but risks include earnings volatility and competitive pressures. Revenue declined to $1.3B in 2026 from $1.4B in 2025, and profit margins compressed, requiring monitoring of operational execution amid energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
